#2026/8Nadir Kanserler Yasası 2026
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
The Rare Cancers Act 2026 aims to promote research and investment in treatments for rare cancers, which affect fewer than 1 in 2000 people in the UK. It requires the Secretary of State to review current laws on marketing authorizations for cancer treatments and to facilitate research into these rare cancers. This law impacts patients with rare cancers, researchers, and healthcare providers.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- The Secretary of State must review marketing authorizations for orphan medicinal products related to cancer.
- A National Specialty Lead for Rare Cancers will be appointed to promote and facilitate research.
- NHS England can disclose information to help identify potential clinical trial participants for rare cancers.
+ 1 more changes with Pro
Obligations
What this law requires
The Secretary of State must carry out a review of the law relating to marketing authorisations for orphan medicinal products for the diagnosis, prevention or treatment of cancer
The Secretary of State must prepare and publish a report setting out the conclusions of the marketing authorisations review
The Secretary of State must publish the review report before the end of three years beginning with the day this Act is passed (by 5th March 2029)
The Secretary of State must consider regulatory approaches in other countries as part of the marketing authorisations review
The Secretary of State must lay a copy of the review report before Parliament